Endometrial Carcinoma
Conditions
Brief summary
This study examines risk assessment and identifies prevention strategies for endometrial cancer. Collecting samples of blood and urine and risk assessments from patients with benign conditions or endometrial cancer may help doctors learn if there is a relationship between chronic inflammation and increase in risk for endometrial cancer.
Detailed description
PRIMARY OBJECTIVE: I. To develop a model for a biobank that can be expanded across the Mayo Enterprise and implemented at extramural collaborative sites, including underserved populations. OUTLINE: This is an observational study. Patients complete a risk factor questionnaire over 15 minutes. Patients also undergo collection of blood and urine during pre-operative visit and collection of tissue samples at the time of surgery.
Interventions
PROCEDUREBiospecimen Collection
Undergo collection of blood, urine, and tissue samples
OTHERQuestionnaire Administration
Complete risk factor questionnaire
Sponsors
Mayo Clinic
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Women over the age of 18 years old undergoing hysterectomy for any benign indication or endometrial cancer
Exclusion criteria
* Men * Women under the age of 18 years * Women with a history of cancer, except for endometrial cancer or non-melanoma skin cancer * Women with type 1 diabetes * Women that have received radiation or chemotherapy for cancer
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Levels of eicosanoids and specialized pro-resolving mediators (SPMs) in visceral adipose tissue (VAT) | Through study completion, up to 24 weeks | Will compare eicosanoid and SPM levels by case-control status (women with endometrial carcinoma and women with non-cancerous conditions) in all patients with linear models, adjusted for age and body mass index (BMI) (and menstrual date, if needed). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Ribonucleic acid (RNA) expression pathways related to inflammation in VAT | Through study completion, up to 24 weeks | Will assess RNA data with cluster analysis and principal component analysis, focusing on inflammatory / immune pathways pathways in 10 patients with endometrioid endometrial cancer and 10 patients with benign conditions, frequency matched on age and body mass index (BMI). We will Will assess RNA expression patterns in relation to eicosanoid / SPMs that discriminate cases versus controls. |
Countries
United States
Outcome results
None listed